We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-2.03%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.01B
AUM Growth
-$490M
Cap. Flow
-$415M
Cap. Flow %
-40.98%
Top 10 Hldgs %
28.64%
Holding
97
New
5
Increased
11
Reduced
69
Closed
8

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18M
2
BNTX icon
BioNTech
BNTX
+$14.3M
3
ALGN icon
Align Technology
ALGN
+$7.3M
4
GDRX icon
GoodRx Holdings
GDRX
+$5.39M
5
CYTK icon
Cytokinetics
CYTK
+$5.15M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$29.9M
2
PFE icon
Pfizer
PFE
+$24.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$23.8M
4
ELV icon
Elevance Health
ELV
+$23.7M
5
MCK icon
McKesson
MCK
+$22.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Industrials 1.09%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
26
Intuitive Surgical
ISRG
$139B
$15.8M 1.56%
52,500
+12,500
+31% +$3.65M
CNC icon
27
Centene
CNC
$32.9B
$15.7M 1.55%
187,000
-68,000
-27% -$5.58M
AXNX
28
DELISTED
Axonics, Inc. Common Stock
AXNX
$15M 1.48%
240,000
-75,000
-24% -$4.04M
BNTX icon
29
BioNTech
BNTX
$23.3B
$14.5M 1.43%
+85,000
New +$14.3M
TMO icon
30
Thermo Fisher Scientific
TMO
$222B
$14M 1.38%
23,750
-20,250
-46% -$11.6M
ALGN icon
31
Align Technology
ALGN
$12.5B
$13.1M 1.29%
30,000
+15,000
+100% +$7.3M
HRMY icon
32
Harmony Biosciences
HRMY
$2.27B
$13.1M 1.29%
268,244
+48,244
+22% +$1.97M
MRTX
33
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.3M 1.22%
149,800
-200
-0.1% -$20.5K
INSP icon
34
Inspire Medical Systems
INSP
$1.73B
$12.2M 1.2%
47,500
+1,127
+2% +$258K
BDX icon
35
Becton Dickinson
BDX
$48.9B
$11.8M 1.17%
45,613
-47,662
-51% -$12.3M
HUM icon
36
Humana
HUM
$46.3B
$11.5M 1.14%
26,500
-28,500
-52% -$11.9M
SWAV
37
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$11.4M 1.12%
54,800
+20,800
+61% +$3.43M
CYTK icon
38
Cytokinetics
CYTK
$10.8B
$10.9M 1.07%
295,000
+145,000
+97% +$5.15M
ABT icon
39
Abbott
ABT
$188B
$10.7M 1.05%
90,000
-10,000
-10% -$1.24M
PRVA icon
40
Privia Health
PRVA
$2.86B
$10.6M 1.05%
397,510
-182,490
-31% -$4.31M
GILD icon
41
Gilead Sciences
GILD
$165B
$10.1M 1%
170,000
-105,000
-38% -$6.71M
DHR icon
42
Danaher
DHR
$147B
$9.97M 0.98%
38,352
-2,256
-6% -$565K
NBIX icon
43
Neurocrine Biosciences
NBIX
$16.8B
$9.84M 0.97%
105,000
-46,100
-31% -$3.91M
XNCR icon
44
Xencor
XNCR
$1.6B
$9.17M 0.9%
343,636
-106,364
-24% -$3.43M
SGEN
45
DELISTED
Seagen Inc. Common Stock
SGEN
$8.79M 0.87%
61,000
-66,000
-52% -$8.93M
VEEV icon
46
Veeva Systems
VEEV
$38.1B
$8.07M 0.8%
38,000
-22,000
-37% -$4.77M
IOVA icon
47
Iovance Biotherapeutics
IOVA
$2.9B
$7.91M 0.78%
475,000
-125,000
-21% -$1.93M
EW icon
48
Edwards Lifesciences
EW
$53B
$7.65M 0.76%
65,000
-35,000
-35% -$3.93M
RCM
49
DELISTED
R1 RCM Inc. Common Stock
RCM
$7.55M 0.75%
282,189
-267,811
-49% -$6.57M
DVAX
50
DELISTED
Dynavax Technologies
DVAX
$7.38M 0.73%
680,676
-69,324
-9% -$842K
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rhenman & Partners Asset Management held 97 positions worth $1.01B, down 33% from $1.5B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $415M in Q1 2022, closing 8 positions and reducing 69 holdings. Its most notable exit was HCA Healthcare, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Regeneron Pharmaceuticals worth $19.9M.

  • Rhenman & Partners Asset Management's largest Q1 2022 buy was Regeneron Pharmaceuticals: 28,500 shares worth $19.9M.
  • Rhenman & Partners Asset Management added most to Align Technology in Q1 2022, an estimated $7.3M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2022 reduction was UnitedHealth, cutting an estimated $29.9M.
  • Rhenman & Partners Asset Management fully exited HCA Healthcare in Q1 2022, selling an estimated $15.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.01B portfolio in Q1 2022.
  • Rhenman & Partners Asset Management opened 5 new positions and closed 8 in Q1 2022.
  • Rhenman & Partners Asset Management's portfolio value fell 33% quarter-over-quarter to $1.01B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2022, filed 13 May 2022.